PMID- 26430929
OWN - NLM
STAT- MEDLINE
DCOM- 20170224
LR  - 20230120
IS  - 1541-1087 (Electronic)
IS  - 0731-5724 (Linking)
VI  - 35
IP  - 6
DP  - 2016 Aug
TI  - The Consumption of Synbiotic Bread Containing Lactobacillus sporogenes and Inulin 
      Affects Nitric Oxide and Malondialdehyde in Patients with Type 2 Diabetes 
      Mellitus: Randomized, Double-Blind, Placebo-Controlled Trial.
PG  - 506-513
AB  - OBJECTIVES: To our knowledge, no reports are available indicating the effects of 
      synbiotic bread consumption on nitric oxide (NO), biomarkers of oxidative stress, 
      and liver enzymes among patients with type 2 diabetes mellitus (T2DM). This study 
      was performed to determine the effects of the daily consumption of synbiotic 
      bread on NO, biomarkers of oxidative stress, and liver enzymes in patients with 
      T2DM. METHODS: This randomized, double-blind, placebo-controlled trial was 
      performed among 81 patients with diabetes, aged 35-70 years old. After a 2-week 
      run-in period, patients were randomly divided into 3 groups: group A (n = 27) 
      received synbiotic bread containing viable and the heat-resistant probiotic 
      Lactobacillus sporogenes (1 x 10(8) CFU) and 0.07 g inulin per 1 g, group B (n = 
      27) received probiotic bread containing Lactobacillus sporogenes (1 x 10(8) CFU), 
      and group C (n = 27) received control bread for 8 weeks. Patients were asked to 
      consume the synbiotic, probiotic, or control breads 3 times a day in 40 g 
      packages for a total of 120 g/day. Fasting blood samples were taken at baseline 
      and after an 8-week intervention for quantificationof related markers. RESULTS: 
      After 8 weeks, the consumption of synbiotic bread compared to the probiotic and 
      control breads resulted in a significant rise in plasma NO (40.6 +/- 34.4 vs 18.5 +/- 
      36.2 and -0.8 +/- 24.5 micromol/L, respectively, p < 0.001) and a significant reduction 
      in malondialdehyde (MDA) levels (-0.7 +/- 0.7 vs 0.6 +/- 1.7 and 0.5 +/- 1.5 micromol/L, 
      respectively, p = 0.001). We did not find any significant effect of the synbiotic 
      bread consumption on plasma total antioxidant capacity (TAC), plasma glutathione 
      (GSH), catalase, serum liver enzymes, calcium, iron, magnesium levels, and blood 
      pressure compared to the probiotic and control breads. CONCLUSION: In conclusion, 
      consumption of the synbiotic bread for 8 weeks among patients with T2DM had 
      beneficial effects on plasma NO and MDA levels; however, it did not affect plasma 
      TAC, GSH, catalase levels, serum liver enzymes, calcium, iron, magnesium levels, 
      and blood pressure.
FAU - Bahmani, Fereashteh
AU  - Bahmani F
AD  - a Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences , Kashan , IRAN.
FAU - Tajadadi-Ebrahimi, Maryam
AU  - Tajadadi-Ebrahimi M
AD  - b Science Faculty, Islamic Azad University, Tehran Central Branch , Tehran , 
      IRAN.
FAU - Kolahdooz, Fariba
AU  - Kolahdooz F
FAU - Mazouchi, Marjan
AU  - Mazouchi M
AD  - a Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences , Kashan , IRAN.
FAU - Hadaegh, Haleh
AU  - Hadaegh H
AD  - c Department of Research and Development of Sahar Bread Company , Tehran , IRAN.
FAU - Jamal, Atefeh-Sadat
AU  - Jamal AS
AD  - a Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences , Kashan , IRAN.
FAU - Mazroii, Navid
AU  - Mazroii N
AD  - a Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences , Kashan , IRAN.
FAU - Asemi, Shiva
AU  - Asemi S
AD  - a Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences , Kashan , IRAN.
FAU - Asemi, Zatolla
AU  - Asemi Z
AD  - a Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences , Kashan , IRAN.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20151002
PL  - United States
TA  - J Am Coll Nutr
JT  - Journal of the American College of Nutrition
JID - 8215879
RN  - 0 (Antioxidants)
RN  - 0 (Biomarkers)
RN  - 0 (Placebos)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 9005-80-5 (Inulin)
RN  - EC 1.11.1.6 (Catalase)
RN  - GAN16C9B8O (Glutathione)
SB  - IM
ECI - J Am Nutr Assoc. 2022 Jan;41(1):125. PMID: 33155885
UIN - J Am Nutr Assoc. 2022 Jan;41(1):125. PMID: 33155885
MH  - Adult
MH  - Aged
MH  - Antioxidants/analysis
MH  - Bacillus coagulans/physiology
MH  - Biomarkers/blood
MH  - Blood Pressure
MH  - Bread/*analysis/microbiology
MH  - Catalase/blood
MH  - Diabetes Mellitus, Type 2/*blood/therapy
MH  - Double-Blind Method
MH  - Glutathione/blood
MH  - Humans
MH  - Inulin/analysis
MH  - Malondialdehyde/*blood
MH  - Middle Aged
MH  - Nitric Oxide/*blood
MH  - Placebos
MH  - Synbiotics/*analysis
OTO - NOTNLM
OT  - diabetes
OT  - nitric oxide
OT  - oxidative stress
OT  - probiotic
OT  - synbiotic
EDAT- 2015/10/03 06:00
MHDA- 2017/02/25 06:00
CRDT- 2015/10/03 06:00
PHST- 2015/10/03 06:00 [pubmed]
PHST- 2017/02/25 06:00 [medline]
PHST- 2015/10/03 06:00 [entrez]
AID - 10.1080/07315724.2015.1032443 [doi]
PST - ppublish
SO  - J Am Coll Nutr. 2016 Aug;35(6):506-513. doi: 10.1080/07315724.2015.1032443. Epub 
      2015 Oct 2.